Objective: To observe the effects of
Ginaton on blood
nitric oxide (NO) and
nitric oxide synthase (NOS) in patients with delayed
encephalopathy after acute
carbon monoxide poisoning (DEACMP). Methods: A total of 116 patients with DEACMP who were treated in Emergency Department of Harrison International Peace Hospital Affiliated to Hebei Medical University from January 2012 to April 2016 were enrolled and ran-domly divided into control group and treatment group using a random number table, with 58 patients in each group. The patients in the control group were given conventional treatment including hyperbaric
oxygen, preven-tion and treatment of
cerebral edema, and promotion of brain cell metabolism, and those in the treatment group were given
Ginaton in addition to the conventional treatment. The course of treatment was 2 weeks for both groups. The levels of
neuron-specific enolase (NSE) , NO, NOS, and
inducible nitric oxide synthase (iNOS) were measured before treatment and at 2 weeks
after treatment, and the change in Mini-Mental State Examina-tion (MMSE) score and clinical outcome were observed in both groups. The correlation between the blood NO level on admission and the MMSE score was analyzed. Results: There was a significant difference in the overall response rate between the treatment group and the control group (81.03% vs 62.07%, χ(2) = 5.124, P=0.024). Be-fore treatment, there were no significant differences in the levels of NO and NSE, the activity of NOS and iN-OS, and MMSE score between the two groups (P>0.05).
After treatment, both groups showed reductions in the levels of NO and NSE and the activity of NOS and iNOS, but the treatment group had significantly greater reduc-tions compared with the control group (P<0.05). Both groups showed a significant increase in the MMSE score
after treatment, while the treatment group had a significantly greater increase compared with the control group (P<0.05). In the patients with DEACMP, the blood NO level on admission was negatively correlated with the MMSE score (r=-0.268, P=0.004). Conclusion: In the treatment of patients with DEACMP,
Ginaton can effectively reduce the levels of NO and NSE and the activity of NOS and iNOS, increase the MMSE score, and promote the recovery of neurological function.